Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets)

Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, Germany.

Source: World Pharma News - October 10, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news